Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Healthcare Costs
Regence BlueCross BlueShield reports more generic versions of Zocor reduces costs
February 14th, 2007
The U.S. Food and Drug Administration (FDA) has approved six additional companies to begin selling generic versions of the cholesterol-lowering drug Zocor (simvastatin), effective December 27, 2006. Previously, only two generic simvastatins competed against Zocor; these drugs were approved in June 2006 and granted 180-day exclusivity, which ended on December 23. "Statin drugs, such as Zocor, Lipitor, and the eight generic simvastatins are proven to be very effective in lowering cholesterol and preventing cardiovascular disease," said David Clark, vice president, Medical and Pharmacy Services, Regence BlueCross BlueShield, which serves the states of...
Source: Medical Patent Law Weekly (2007-02-14)
|
